Benzinga -- Deutsche Bank has published a company alert today on Merck & Co. following results of the SHARP trial. In a note to clients, Deutsche Bank writes, "The SHARP trial compared vascular/atherosclerotic outcomes with Vytorin 10/20 therapy to placebo in 9,400 chronic kidney disease patients (approx. 1/3 on dialysis) with 5 years of followup. Results were positive overall, and no major safety concerns emerged, suggesting that MRK will be able to gain approval for the supplemental indication."
